PURPOSE OF REVIEW: To review the available data on the outcomes of pediatric and adult patients with acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia after umbilical cord blood transplantation. RECENT FINDINGS: The literature shows that after umbilical cord blood transplantation the relapse rate, disease-free survival and overall survival of patients with myeloid malignancies is similar to other hematopoietic stem cells sources. Disease status at the time of transplantation is found in several studies to be a very important determinant of long-term outcome. Newer strategies such as double umbilical cord blood transplant and utilization of nonmyeloblative conditioning regimens show promising results. SUMMARY: Umbilical cord blood is a valuable alternative source of hematopoietic stem cells for transplantation of patients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor.
PURPOSE OF REVIEW: To review the available data on the outcomes of pediatric and adult patients with acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia after umbilical cord blood transplantation. RECENT FINDINGS: The literature shows that after umbilical cord blood transplantation the relapse rate, disease-free survival and overall survival of patients with myeloid malignancies is similar to other hematopoietic stem cells sources. Disease status at the time of transplantation is found in several studies to be a very important determinant of long-term outcome. Newer strategies such as double umbilical cord blood transplant and utilization of nonmyeloblative conditioning regimens show promising results. SUMMARY: Umbilical cord blood is a valuable alternative source of hematopoietic stem cells for transplantation of patients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor.
Authors: Mei-Jie Zhang; Stella M Davies; Bruce M Camitta; Brent Logan; Karin Tiedemann; Mary Eapen; Elizabeth L Thiel Journal: Biol Blood Marrow Transplant Date: 2012-03-06 Impact factor: 5.742
Authors: Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein Journal: Blood Date: 2011-08-03 Impact factor: 22.113
Authors: Erica D Warlick; Regis Peffault de Latour; Ryan Shanley; Marie Robin; Nelli Bejanyan; Alienor Xhaard; Claudio Brunstein; Flore Sicre de Fontbrune; Celalettin Ustun; Daniel J Weisdorf; Gerard Socie Journal: Biol Blood Marrow Transplant Date: 2014-11-06 Impact factor: 5.742
Authors: Lisa J Giassi; Todd Pearson; Leonard D Shultz; Joseph Laning; Kristin Biber; Morey Kraus; Bruce A Woda; Madelyn R Schmidt; Robert T Woodland; Aldo A Rossini; Dale L Greiner Journal: Exp Biol Med (Maywood) Date: 2008-08
Authors: Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele Journal: Nat Rev Clin Oncol Date: 2012-09-04 Impact factor: 66.675